Xontogeny
Finance · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
240 Newbury St Ste 201, Boston, Massachu...Phone Number
(857) 891-0017Website
www.xontogeny.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
2
1
1
1
About Xontogeny
Xontogeny is a life sciences accelerator that partners with entrepreneurs, scientific founders, and first-time CEOs to facilitate the successful development of technologies aimed at providing new treatment options for patients with serious diseases. The company leverages its experienced team and extensive network of industry consultants, along with seed investment capital, across various sectors including therapeutics, diagnostics, and devices. Xontogeny focuses on guiding each program through critical clinical proof-of-concept studies. With a commitment to collaboration, it aims to accelerate the advancement of new technologies and strengthen connections within the life sciences community.Explore more
Xontogeny Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xontogeny your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Xontogeny had a recent Job posting/layoffs
Earning: See what the market has to say on Xontogeny recently announced quarterly report
Xontogeny, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Xontogeny has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Xontogeny
Funding: Get notified immidiatlly once Xontogeny has new funding data
Product Launch: Get notified when Xontogeny launches new products
Website visits: Recent activity has been detected on your website
Check out if Xontogeny is spiking on competitors!
Recommended Actions
Find VP level buyers at Xontogeny
Find more new buyers
Compare Similar Companies to Xontogeny
Compare insights from companies similar to Xontogeny, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Xontogeny is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Xontogeny is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Xontogeny.
Xontogeny financials insights
Gather financial insights about Xontogeny, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$15M
Xontogeny Tech Stack
A closer look at the technologies used by Xontogeny
See more technologies
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Facilities Relocation / Expansion
Xontogeny is planning to move its offices in January 2023. The move will impact employees at their existing office located at 240 Newbury Street, Suite #201, Boston, MA.
Lateral Move
Executive Move
Xontogeny News & Media
PolyCore Therapeutics Secures Seed Financing to Address Motor Symptoms and Dyskinesia Associated with Parkinson’s Disease
PHILADELPHIA--(BUSINESS WIRE)--PolyCore Therapeutics, Inc., a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced a seed investment from Xontogeny, LLC and Ben Franklin Technology Partners of Southeastern Pennsylvania to advance their lead compound, PCT-3012, a novel G protein-biased D3 receptor agonist to reduce motor impairment in Parkinson’s Disease, through IND-enabling wBoston-based Xontogeny makes seed investments in 3 Philadelphia-area life sciences startups
These three Philadelphia-area life sciences companies have secured seed financing from a Boston-based business accelerator and investor.Perceptive Advisors unveils $515M fund, its 2nd for early-stage biotechs
After 20 years of backing clinical-stage biotechs, Perceptive Advisors took a leap in 2019, teaming up with Chris Garabedian’s Xontogeny to invest in earlier-stage companies. Less than 18 months later, that crew is back for round two, with a new fund totaling $515 million. Dubbed the Perceptive Xontogeny Fund II, the capital will bankroll series A rounds of $20 million to $40 million.
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xontogeny
Sign Up For FreeTo access detailed company insights
Xontogeny is a life sciences accelerator that partners with entrepreneurs, scientific founders, and first-time CEOs to facilitate the successful development of technologies aimed at providing new treatment options for patients with serious diseases. The company leverages its experienced team and extensive network of industry consultants, along with... Read More
